# US 2001/0024803 A1 · Induced aggregation and agglutination of platelets

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024803 A1
- Document ID: US20010024803A1
- Status: Published application
- Kind: A1
- Application number: 09/809,062
- Filed: 2001-03-16
- Published: 2001-09-27
- Earliest claimed: 2000-03-17
- Assignees: Dade Behring Marburg GmbH
- Inventors: Jurgen Patzke
- Web page: https://patentgrep.com/patent/US20010024803A1

## CPC

- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a method for measuring the aggregation or agglutination of platelets, where a reaction mixture is mixed in a first reaction phase, and is mixed less vigorously or not at all in a second reaction phase following the first, and the measurement is preferably carried out in the second reaction phase.

## Claims

### Claim 1

A method for measuring the aggregation of blood platelets, where a reaction mixture is mixed in a first reaction phase, and is mixed less vigorously or not at all in a second reaction phase following the first, where the measurement is preferably carried out in the second reaction phase.

### Claim 2 (depends on 1)

The method as claimed in claim 1, where the mixing takes place by stirring, shaking, vibrating or ultrasound.

### Claim 3 (depends on 1, 2)

The method as claimed in claim 1 or 2 for determining the aggregation of physiologically active blood platelets.

### Claim 4 (depends on 1, 2)

The method as claimed in either of claims 1 or 2 for determining the aggregation of fixed blood platelets, in particular in the ristocetin cofactor test.

### Claim 5 (depends on 1, 2, 3)

The method as claimed in any of claims 1 to 3, where whole blood, platelet-rich plasma, diluted platelet-rich plasma or purified platelets are employed as sample for the measurement.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method as claimed in any of claims 1 to 5, where turbidimetric or nephelometric methods are employed for measuring the aggregate formation.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method as claimed in any of claims 1 to 5, where electromagnetic methods are employed for measuring the aggregate formation.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method as claimed in any of claims 1 to 7, where the mixing time necessary for inducing the aggregation reaction is determined.

### Claim 9 (depends on 8)

The method as claimed in claim 8 for determining the sensitivity of blood platelets to platelet activators such as, for example, ristocetin, collagen, ADP, epinephrine or arachidonic acid.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

A method for determining the stability of platelet aggregates, where the aggregation in a method as claimed in any of claims 1 to 7 is compared with an analogous measurement with continuous stirring.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method as claimed in any of claims 1 to 10, where an incubation phase without mixing is inserted before the mixing phase.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method as claimed in any of claims 1 to 11, where an initial measurement is determined before the mixing phase.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method as claimed in any of claims 1 to 12, where the extent of the aggregation is determined by counting the remaining unaggregated platelets.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method as claimed in any of claims 1 to 13, where the aggregation of blood platelets and particles is measured.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method as claimed in any of claims 1 to 14, where in place of blood platelets there is use of other cells, membrane vesicles or artificial particles.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method as claimed in any of claims 1 to 15, where the mixing is not completely stopped but the mixing is adjusted to a lower intensity.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method as claimed in any of claims 1 to 16, where there is a sequence of a plurality of mixed and unmixed phases.
